Compounds > cbm 4a
Page last updated: 2024-12-07

cbm 4a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

chlorobromofosfamide: the bromo analog of ifosfamide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126997
CHEMBL ID336035
SCHEMBL ID9062899
MeSH IDM0257455

Synonyms (11)

Synonym
2h-1,3,2-oxazaphosphorin-2-amine, tetrahydro-3-(2-bromoethyl)-n-(2-chloroethyl)-, 2-oxide, (+-)-
2h-1,3,2-oxazaphosphorin-2-amine, 3-(2-bromoethyl)-n-(2-chloroethyl)tetrahydro-, 2-oxide, (+-)-
chlorobromofosfamide
CHEMBL336035
cbm 4a
cbm-4a
146367-82-0
SCHEMBL9062899
3-(2-bromoethyl)-2-[(2-chloroethyl)amino]-1,3,2lambda~5~-oxazaphosphinan-2-one
DTXSID50932822
3-(2-bromoethyl)-n-(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Ifosfamide, although itself the effective antineoplastic drug useful in situations which have proved refractory to cyclophosphamide therapy, has the side-effect toxicities caused by its metabolities that pose clinically a very real problem."( Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
Konarski, L; Kowalski, P; Kuśnierczyk, H; Radzikowski, C, 1997)		0.3

Bioavailability

ExcerptReferenceRelevance
"Three bromine-ifosfamide analogues: racemic chlorobromofosfamide (+/-)-(R,S)-1, its levorotatory enantiomer (-)-(S)-2 and racemic bromofosfamide (+/-)-(R,S)-3 showed considerable stereoselective differences in their pharmacokinetics and bioavailability depending on the route of administration and regimen of dosage studies in rats."( Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide.
Hładoń, B; Kinas, R; Kuśnierczyk, H; Laskowska, H; Sloderbach, A; Sochacki, M, )		0.13

Dosage Studied

ExcerptRelevanceReference
"Three bromine-ifosfamide analogues: racemic chlorobromofosfamide (+/-)-(R,S)-1, its levorotatory enantiomer (-)-(S)-2 and racemic bromofosfamide (+/-)-(R,S)-3 showed considerable stereoselective differences in their pharmacokinetics and bioavailability depending on the route of administration and regimen of dosage studies in rats."( Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide.
Hładoń, B; Kinas, R; Kuśnierczyk, H; Laskowska, H; Sloderbach, A; Sochacki, M, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID115147Maximum tolerated dose against L1210 leukemia in mice2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Studies on the side-chain hydroxylation of ifosfamide and its bromo analogue.
AID112166Effective dose that produce antitumor activity against L1210 leukemia in mice2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Studies on the side-chain hydroxylation of ifosfamide and its bromo analogue.
AID211869Dose required to induce cytotoxicity against L1210 leukemia in mice2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Studies on the side-chain hydroxylation of ifosfamide and its bromo analogue.
AID235229Therapeutic index represented as LD50/ED50 was determined2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Studies on the side-chain hydroxylation of ifosfamide and its bromo analogue.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's4 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ifosfamide
[no description available]		3.2660ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
mesna
Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.		1.9910organosulfonic acid
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		02.0110
HPV Infection
[description not available]		02.0510
Experimental Neoplasms
[description not available]		02.7230
Papillomavirus Infections
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.		02.0510
Metastase
[description not available]		02.0110
Cell Transformation, Viral
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.		02.0110
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.0110
Minimal Disease, Residual
[description not available]		02.0310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0310
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9810
Anasarca
[description not available]		01.9910
Bleeding
[description not available]		01.9910
Cystitis
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.		01.9910
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		01.9910
Hemorrhage
Bleeding or escape of blood from a vessel.		01.9910
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		01.9910